[Clinical case of levamisole-induced multifocal inflammatory leukoencephalopathy].
Autor: | Averchenkov DM; Bujanov Moscow City Clinical Hospital, Moscow, Russia., Bejsheeva MT; Bujanov Moscow City Clinical Hospital, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia., Ivakina ED; Pirogov Russian National Research Medical University, Moscow, Russia., Fominykh VV; Bujanov Moscow City Clinical Hospital, Moscow, Russia; Institute of Higher Nervous Activity and Neurophysiology, Moscow, Russia., Grazhdantseva LY; Bujanov Moscow City Clinical Hospital, Moscow, Russia., Ivashchenko RA; Bujanov Moscow City Clinical Hospital, Moscow, Russia., Arzumanian NS; Bujanov Moscow City Clinical Hospital, Moscow, Russia., Brylev LV; Bujanov Moscow City Clinical Hospital, Moscow, Russia; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Guekht AB; Bujanov Moscow City Clinical Hospital, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia. |
---|---|
Jazyk: | ruština |
Zdroj: | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2019; Vol. 119 (12), pp. 106-114. |
DOI: | 10.17116/jnevro2019119121106 |
Abstrakt: | Levamisole is an immunomodulatory drug which can trigger development of levamisole-induced multifocal inflammatory leukoencephalopathy (LIMIL) in patients treated for helminthic invasion, aphthous stomatitis, cancer, or cocaine users. LIMIL clinical case in patient 45 years old after single dose of levamisole (taken without any medical prescription) was described. We presented clinical history and clinical picture, MRI and laboratory data and treatment results during 1-year observation. According to similarity of LIMIL with acute disseminating encephalomyelitis or debut of multiple sclerosis and high frequency of levamisole usage in Russia (usually without medical prescription) LIMIL should be included in differential diagnosis in demyelinating disorders and treated according to current clinical recommendation. |
Databáze: | MEDLINE |
Externí odkaz: |